Over 180 Papers Listed on PubMed | Chief Investigator of the £3 Million PRESIDENT Trial
Professor Sooriakumaran is helping shape the future of prostate cancer treatment through pioneering research. At the University of Oxford, he leads the £3 million NIHR-funded PRESIDENT trial, involving at least 25 UK centres, investigating whether surgery can improve survival and quality of life in men with limited metastatic prostate cancer.
Building on his TRoMbone trial, his research spans robotic prostate surgery, Retzius-sparing techniques, urinary continence and AI-assisted recovery prediction. Explore his publications below, with summaries and links to the original research.
Oxford PRESIDENT Trial & Prostate Cancer Research
Prostate cancer research by Professor Prasanna Sooriakumaran, Chief Investigator of the £3m University of Oxford PRESIDENT trial, funded by the Department of Health and Social Care.
2024–2026 (6 papers)
Oncological and continence outcomes after nerve-sparing robot-assisted radical prostatectomy in selected STAMPEDE-defined high-risk prostate cancer
Bilé-Silva A (first author), BJU Int 2026
Among 1,385 men operated on in 2021–2022, nerve-sparing was used in 57.3% of those with two or more high-risk factors, with similar positive margins (21.3% vs 23.2%) and 12-month biochemical recurrence (6.7% vs 5.4%) to non-nerve-sparing. Continence was similar at 3 and 12 months, with fewer pads at 12 months after nerve-sparing (P = 0.03).
The PART randomised trial protocol: Partial Ablation versus Radical Treatment for prostate cancer
Bryant RJ (first author), BJU Int 2026
Protocol for a UK-wide RCT testing whether partial ablation (HIFU or irreversible electroporation) is non-inferior to radical treatment for localised intermediate-risk disease, on oncological treatment success with a 20% margin. It needs 275 randomised men, or 306 allowing for 10% dropout; no results are reported.
Radical Prostatectomy in Low-volume Metastatic Prostate Cancer? The Need for New Evidence
Sooriakumaran P (first author), Eur Urol 2026
Editorial with no abstract on PubMed. The title sets out the case for new evidence on prostatectomy in low-volume metastatic disease.
AI based prediction of post prostatectomy urinary incontinence and its impact on quality of life: development and validation study
Hadjivasiliou A (first author), Sci Rep 2026
XGBoost models built on 21 perioperative features from 2,586 patients (2018–2021) were validated on 728 patients from 2022. For men still incontinent at 3 months, 12-month prediction reached AUC 0.82–0.86, while 3-month prediction from baseline features alone was modest (AUC 0.52–0.59).
Retzius-sparing robot-assisted radical prostatectomy in renal transplant recipients
Leow JJ (first author), BJU Int 2025
No abstract on PubMed. The title describes Retzius-sparing prostatectomy in renal transplant recipients.
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Nagasubramanian S (first author), J Endourol 2025
Technique paper covering indications, contraindications, preparation, surgical steps and postoperative care for the Retzius-sparing approach, which may allow earlier return of continence. It also covers special scenarios: anterior tumours, large median lobes, prior bladder outlet surgery and renal transplant recipients.
2022–2023 (9 papers)
Does Radical Local Treatment in Oligometastatic Prostate Cancer Improve Overall Survival: A Systematic Review and Meta-analysis
Madhavan K (first author), Urology 2023
Meta-analysis of three RCTs found higher overall survival with radical local treatment plus standard care than standard care alone (HR 0.643, 95% CI 0.514–0.8), with similar quality of life. Most data came from radiotherapy (520 patients) and only 85 had prostatectomy, so the authors urged caution.
Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended? Of Course Not!
Sooriakumaran P (first author), Eur Urol Open Sci 2022
No abstract on PubMed. The title argues against extended pelvic lymph node dissection at prostatectomy.
Nightmares in Salvage Robot-assisted Radical Prostatectomy After Primary Radiation Therapy for Prostate Cancer: A Step by Step Tutorial
Marquis A (first author), Eur Urol Open Sci 2022
Educational video and non-systematic review of critical steps and complications in salvage prostatectomy after radiotherapy. Reported rates were bladder neck contracture 0–16%, anastomotic leak 10–33%, rectal injury under 2% and severe incontinence in about 25%.
Retzius-sparing technique independently predicts early recovery of urinary continence after robot-assisted radical prostatectomy
Kadhim H (first author), J Robot Surg 2022
In 431 patients, 59 (13.7%) of whom had Retzius-sparing surgery, 55.9% were pad-free at 3 months. Retzius-sparing technique independently predicted early continence (HR 2.19, 95% CI 1.15–4.16), as did younger age.
Primary Tumour Treatment in Oligometastatic Prostate Cancer: Radiotherapy Versus Radical Prostatectomy
Ting F (first author), Eur Urol Open Sci 2022
No abstract on PubMed. The title compares radiotherapy and prostatectomy as primary tumour treatment in oligometastatic disease.
Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options
Narain TA (first author), World J Mens Health 2022
Review comparing newer blood and urinary biomarkers with serum PSA for screening, diagnosis and risk stratification. It suggests that combining these markers with clinical risk factors and advanced imaging could improve diagnostic performance.
Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the TRoMbone trial
Sooriakumaran P (first author), BJU Int 2022
UK feasibility RCT of adding prostatectomy with pelvic lymphadenectomy to standard systemic therapy randomised 51 men in 14 months against a target of 50. Surgery appeared safe and quality of life was similarly high in both arms.
Comparative Effectiveness Analyses of Salvage Prostatectomy and Salvage Radiotherapy Outcomes Following Focal or Whole-Gland Ablative Therapy for Localised Prostate Cancer
Nathan A (first author), Clin Oncol (R Coll Radiol) 2022
Comparison of 100 salvage robotic prostatectomies with 100 salvage radiotherapy cases after failed ablation. Radiotherapy gave better 3-year biochemical recurrence-free survival in high-risk men (86.3% vs 66.0%), similar results in intermediate-risk men, and better preserved erectile function.
Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments
Fossati N (first author), Eur Urol Oncol 2022
Case-based review of a 56-year-old man treated with androgen deprivation, robotic prostatectomy with node dissection and postoperative radiotherapy. It frames open questions on PSMA PET/CT staging, local treatment in metastatic disease and metastasis-directed therapy.
2020–2021 (18 papers)
Centralisation of Care for Prevalent Urological Malignancies: The Case for Prostate Cancer
Nathan A (first author), Eur Urol Focus 2021
Narrative mini-review of whether hub-and-spoke centralisation of prostate cancer services has improved outcomes, resource use and costs. It weighs the positive and negative effects on health systems and patients; no pooled figures.
Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk KJ (first author), J Urol 2021
In 72 salvage cases across 9 centres (40 Retzius-sparing, 32 standard), Retzius-sparing had shorter console time and less blood loss with similar complications and oncological outcomes. Continence was better (0–1 pad in 78.4% vs 43.8%) and came sooner (median 47 vs 180 days).
New recommendations to reduce unnecessary blood tests after robot-assisted radical prostatectomy
Nathan A (first author), BJU Int 2021
No abstract on PubMed. The title proposes recommendations to cut unnecessary postoperative blood tests after robotic prostatectomy.
Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre
Nathan A (first author), Eur Urol Open Sci 2021
135 salvage prostatectomies were propensity-matched 1:1 with primary cases from 3,852 consecutive patients. Perioperative outcomes and 2-year pad-free continence were similar (78.8% vs 84.3%), but salvage had more biochemical recurrence (31.9% vs 14.1%) and erectile dysfunction (94.8% vs 76.3%).
In Reply: Prostate cancer screening
Sooriakumaran P (first author), Cleve Clin J Med 2021
Author reply to correspondence; no abstract on PubMed. It relates to the PSA screening article in the same journal.
Outcomes of the RAFT trial: robotic surgery after focal therapy
Cathcart P (first author), BJU Int 2021
Prospective single-arm trial of salvage robotic prostatectomy in 23 men with recurrence after focal therapy. Continence returned to baseline at 12 months (96% using 0–1 pads), sexual function declined, there was one minor complication, and 12-month biochemical recurrence-free survival was 82.6%.
Prostate cancer screening and the role of PSA: A UK perspective
Sooriakumaran P (first author), Cleve Clin J Med 2021
No abstract on PubMed. The title gives a UK perspective on PSA-based prostate cancer screening.
Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients
Umari P (first author), J Urol 2021
Prospective comparison of 282 Retzius-sparing and 201 standard cases by three surgeons found higher immediate continence with Retzius-sparing (70.4% vs 58.1%) and better quality of life at one week. Longer-term functional, oncological and complication outcomes to 12 months were similar.
Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents
Galfano A (first author), BJU Int 2021
First 50 Retzius-sparing cases of 14 surgeons at 12 centres (626 patients): console time, early continence and complications were acceptable from the start and improved with experience. Positive margin rates did not clearly improve over the first 50 cases.
Comparing a new risk prediction model with prostate cancer risk calculator apps in a Taiwanese population
Chen IHA (first author), World J Urol 2021
A new logistic regression model and the Rotterdam app discriminated better than the Coral app for any and high-grade cancer in Taiwanese men undergoing biopsy. At a 10% high-grade risk threshold the model would have avoided 67.2% of biopsies, missing 3.4% of high-grade cancers among those avoided.
High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and Fistulae
Dosanjh A (first author), Eur Urol Focus 2021
English national data on 1,990 patients and 2,320 HIFU treatments (2007–2018) showed rising use, mostly at low-volume centres. With at least one year of follow-up, urethral stricture occurred in 10.3% and fistula in 1.3%, rates not lower than established therapies.
Corrigendum to "A standard operating technique to facilitate early return of urinary continence after robotic prostatectomy: outcomes of a consensus meeting of experts with experience of over 30,000 cases"
Sridhar AN (first author), Eur Urol Open Sci 2020
Corrigendum to a 2017 Eur Urol Suppl abstract; no abstract on PubMed. The original item reported an expert consensus technique for early continence after robotic prostatectomy.
Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study
Chen IA (first author), J Med Internet Res 2020
In 1,134 Taiwanese men undergoing transrectal biopsy, the Rotterdam app outperformed the Coral app for any cancer (AUC 0.779 vs 0.687) and high-grade cancer (AUC 0.862 vs 0.758). The difference was not significant in the small prostatectomy subgroup.
Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation
Thompson JE (first author), BMC Urol 2020
In 45 men having salvage prostatectomy after focal HIFU, surgery was safe with mostly mild complications and 65.5% were pad-free at 12 months. Erectile function was poor, positive margins occurred in 44.4%, and about one in three needed further treatment within 12 months.
Techniques and Outcomes of Salvage Robot-Assisted Radical Prostatectomy (sRARP)
De Groote R (first author), Eur Urol 2020
In 106 salvage cases, most after HIFU, the 90-day complication rate was 8%, positive margins 39% and biochemical recurrence 13%. At two or more years half were fully continent and 95% had erectile dysfunction: feasible in high-volume centres but functionally inferior to primary surgery.
The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W (first author), BJU Int 2020
Review of nine ongoing RCTs of cytoreductive prostatectomy in newly diagnosed hormone-sensitive metastatic disease. Trials differ in primary endpoint, inclusion criteria and follow-up, so each design must be considered when interpreting its results.
Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study
Preisser F (first author), J Urol 2020
In 9,742 prostatectomy patients, propensity-matched where nodal invasion risk exceeded 5%, 10-year biochemical recurrence-free survival was 60.4% with dissection and 65.6% without (p = 0.07). Metastasis-free and cancer-specific survival did not differ, leaving therapeutic value unclear.
Retzius sparing robotic assisted radical prostatectomy vs. conventional robotic assisted radical prostatectomy: a systematic review and meta-analysis
Phukan C (first author), World J Urol 2020
Meta-analysis of six studies found better early continence with Retzius-sparing at one month (RR 1.72) and three months (RR 1.39). Positive margin rates did not differ significantly, with a non-significant trend toward more margins after Retzius-sparing.
2018–2019 (19 papers)
Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer
Tan WS (first author), Clin Genitourin Cancer 2019
US National Cancer Database study of 45,426 men with pT2 disease at 1,152 hospitals found a median positive margin rate of 8.5%. Minimally invasive surgery, academic centres and high volume were linked to lower rates; facility explained 23.7% of the variation and cancer factors 15.2%.
Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy?
Marenco J (first author), Arch Esp Urol 2019
Narrative review of local treatment, including surgery to the primary, in oligometastatic disease. Retrospective data support the ongoing randomised trials, but more data are needed before it can be standard care.
PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilizing magnetic resonance imaging data to target tumor and benign tissue in fresh radical prostatectomy specimens
Heavey S (first author), Prostate 2019
An MRI-guided pathway for sampling tumour and benign tissue from fresh robotic prostatectomy specimens, tested in 84 cases, hit tumour fully or partly in 64% of the initial cohort and 70% of the optimised cohort. High-quality DNA was obtained from 39 tumour samples and ex vivo culture was done in three cases.
Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound
Thompson JE (first author), J Urol 2019
In 35 men having salvage prostatectomy after focal HIFU, significant cancer lay within the treated field in 97.1% and the positive margin rate was 40%. MRI sensitivity was 81.8% for in-field recurrence and 60.7% for out-of-field disease.
Perioperative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon-reported data
Aning JJ (first author), BJU Int 2019
BAUS registry analysis of 3,671 high-risk prostatectomies in 2014–2015 (26.3% of all prostatectomies): 60.7% were robotic and 33.8% had no lymph node dissection. Grade III or higher complications were rare (2.0%) and no surgeon-volume effect was found.
Surgery Versus Radiation for High-risk Prostate Cancer: The Fight Continues. But Is It Time To Call a Draw and Reach Consensus?
Sooriakumaran P (first author), Eur Urol 2019
Editorial comment; no abstract on PubMed. The title asks whether surgery and radiotherapy for high-risk disease should be regarded as equivalent.
Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study
Bryant RJ (first author), J Urol 2019
Comparing 997 men biopsied without MRI and 792 with prebiopsy MRI plus targeted and systematic biopsy, overall cancer detection was unchanged (56.7% vs 57.6%). Omitting systematic biopsy after a negative MRI would have missed 15.1% of Grade Group 2 or higher cancers.
Imaging modalities in synchronous oligometastatic prostate cancer
Futterer JJ (first author), World J Urol 2019
Review of imaging for synchronous oligometastatic disease from a December 2017 PubMed search. 68Ga-PSMA PET-CT gave the best detection of nodal, bone and visceral metastases, especially small lesions at low PSA, but is not available everywhere.
Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?
Ploussard G (first author), World J Urol 2019
Literature review: adding systematic to targeted biopsy raised overall detection by about 30% and significant cancer detection by about 10%. A purely targeted strategy risks missing up to 15% of significant cancers.
Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment
van den Bergh R (first author), Eur Urol Focus 2019
Across four European centres (2000–2015), surgical cases suitable for active surveillance fell from 31% to 5% while high-risk cases rose from 10% to 30%. Men with only localised Gleason 6 disease at final pathology dropped from 46% to 8%.
Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT
Hamdy FC (first author), Health Technol Assess 2018
Feasibility study at five NHS hospitals randomised 82 men with unilateral intermediate-risk disease to HIFU or prostatectomy (41 per arm) against a target of 80. Return rates were 95% for case report forms and 90.5% for patient-reported outcomes, and a full RCT was judged feasible.
Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer
Elliott D (first author), BJU Int 2018
Qualitative study within PART using 13 recruiter interviews and 64 recorded consultations found recruiters' treatment preferences compromised equipoise. After feedback and training, mean recruitment rose from 1.4 to 4.5 patients per month.
How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator
Gandaglia G (first author), BJU Int 2018
A risk score for unfavourable pathology was built from 16,049 prostatectomy patients. An 18% threshold raised the share eligible for active surveillance from 20.6% (PRIAS criteria) to 29.4% without increasing misclassification.
Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?
Bryant RJ (first author), BJU Int 2018
Among 445 active surveillance patients, about 30% stopped surveillance and time to treatment did not differ between systematic repeat biopsy and MRI-based pathways (1.9 vs 1.33 years, P = 0.747). Among men re-biopsied, more in the MRI-targeted group stopped surveillance (44% vs 37%, P = 0.003).
Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology
van den Bergh RCN (first author), World J Urol 2018
Five castration-resistant prostate cancer guidelines were appraised with AGREE-II. Editorial independence (92%) and clarity (83%) scored highest; stakeholder involvement (56%) and applicability (40%) scored lowest and varied most.
Surgery for oligometastatic prostate cancer: ready for prime time?
Sooriakumaran P (first author), BJU Int 2018
Editorial comment; no abstract on PubMed. The title asks whether surgery for oligometastatic disease is ready for routine use.
Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV)
Watson EK (first author), Eur J Oncol Nurs 2018
Pilot RCT enrolled 83 of 136 eligible men (61%) and 87% completed follow-up, showing the intervention was feasible and acceptable. It gave only small gains in unmet needs and self-efficacy and no difference in prostate-related quality of life or psychological morbidity.
Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial
Sooriakumaran P (first author), Eur Urol 2018
Prospective non-randomised Swedish trial of 2,545 men (753 open, 1,792 robotic) found earlier erectile recovery at 3 months after robotic surgery in low- and intermediate-risk patients. Positive margins were 10% open vs 17% robotic in pT2 and 48% vs 33% in pT3, predicting recurrence only in pT3.
Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up
Rajan P (first author), Eur Urol Focus 2018
In 885 men treated by robotic prostatectomy alone in 2002–2006 (median follow-up 10.5 years), biochemical recurrence-free survival was 81.8%, cancer-specific survival 98.5% and overall survival 93.0%. Margins over 3 mm or multifocal predicted recurrence; margins of 3 mm or less did not.
2016–2017 (16 papers)
Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study
Rajan P (first author), J Clin Oncol 2017
Swedish population study of 118,543 men diagnosed 1998–2012 (median follow-up 8.3 years). After adjusting for patient, tumour and treatment characteristics, comorbidity no longer affected prostate cancer-specific mortality but still affected other-cause mortality.
Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer
Sridhar AN (first author), Curr Urol Rep 2017
Review proposing a composite technique: sphincter and neural preservation, maximal urethral length, a secure anastomosis, and anterior and posterior support. Randomised evidence is still needed to confirm benefit.
Tumour heterogeneity poses a significant challenge to cancer biomarker research
Cyll K (first author), Br J Cancer 2017
Multi-sample analysis in 304 prostatectomy patients (median follow-up 10 years) found heterogeneity in 89% for Gleason score and 40% for DNA ploidy. DNA ploidy stayed prognostic once heterogeneity was accounted for, so multi-sample analysis is recommended.
Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial
Sooriakumaran P (first author), BJU Int 2017
Protocol for the TRoMbone feasibility RCT of prostatectomy in men with bone oligometastases. No results are reported.
Metformin and Prostate Cancer: a New Role for an Old Drug
Whitburn J (first author), Curr Urol Rep 2017
Review of preclinical, retrospective and ongoing trial evidence: metformin shows antineoplastic effects through several pathways, with early signals in men on androgen deprivation. Randomised data remain insufficient, though it may be a useful adjuvant.
Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy
Sooriakumaran P (first author), Eur Urol 2017
Swedish population study of men with PSA above 50 treated with radiotherapy (630), prostatectomy (120) or androgen deprivation (17,602), followed up to 15 years. In 575 matched pairs, initial androgen deprivation carried nearly three times the hazard of prostate cancer death (HR 2.87, 95% CI 2.16–3.82).
Neural supply of the male urethral sphincter: comprehensive anatomical review and implications for continence recovery after radical prostatectomy
Bessede T (first author), World J Urol 2017
Review of 17 anatomical articles (254 subjects): all described somatic and autonomic pathways, and 13 reported autonomic fibres from the pelvic plexus or neurovascular bundles. Surgeons should preserve these nerves where possible, though continence is multifactorial.
Oligometastatic Prostate Cancer
Stevens DJ (first author), Curr Treat Options Oncol 2016
Review arguing that men with three or fewer non-castrate metastases may benefit from radical treatment of the primary plus metastasis-directed therapy, on retrospective data. It recommends restricting this to high-volume centres, counselling on uncertain benefit and awaiting RCTs.
The importance of surgical margins in prostate cancer
Sooriakumaran P (first author), J Surg Oncol 2016
Review of positive margins as a predictor of biochemical recurrence and their dependence on surgeon experience and approach. Margins matter less than Gleason score, stage and PSA, but lower rates reduce secondary treatment and anxiety.
The Utility of Molecular Imaging in Prostate Cancer
Leiblich A (first author), Curr Urol Rep 2016
Review of hyperpolarised MRI, choline PET/CT and PSMA PET/CT. Choline and PSMA PET/CT are mainly useful for detecting early recurrence after radical treatment and locating lesions suitable for salvage therapy.
Role of multiparametric magnetic resonance imaging in early detection of prostate cancer
De Visschere PJ (first author), Insights Imaging 2016
Review of multiparametric MRI with PI-RADS reporting: it may reduce overdetection of insignificant cancer and improve detection of significant cancer. Guidelines recommend it for rising PSA after negative biopsy, and it may guide targeted biopsy or surveillance.
Reply from Authors: The Time Is Ripe to Test the Hypothesis that Radical Prostatectomy Improves Survival in Men with Distant Metastatic Prostate Cancer
Sooriakumaran P (first author), Eur Urol 2016
Reply to two editorials (Voogd and Verhoeven; Neugut and Gelmann) on treating the primary in metastatic disease; no abstract on PubMed. The title calls for testing whether prostatectomy improves survival in distant metastatic disease.
A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation
Sooriakumaran P (first author), Eur Urol 2016
In 106 men from four countries, 79.2% had no complications, but positive margins (53.8%) and lymphocele (8.5%) were more common than after standard-indication open surgery. At median 22.8 months 88.7% were alive, suggesting surgery is reasonably safe in selected patients.
Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives
Bayne CE (first author), Eur Urol 2016
Review of 1990–2014 literature found no RCT comparing local plus systemic therapy with systemic therapy alone in metastatic disease. Evidence was preclinical or retrospective and insufficient for routine recommendation.
Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up
Watson E (first author), BJU Int 2016
Postal survey of men 9–24 months after diagnosis at two UK centres (316 responders): moderate or big urinary, bowel and sexual problems in 15.2%, 5.1% and 36.5%. 17% had possible moderate-to-severe anxiety and 10.2% depression, with worse wellbeing in men with side effects.
Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey
Bultijnck R (first author), Eur Urol Focus 2016
Of 489 European clinicians surveyed in 2015, 85% used at least one evidence-based preventive strategy but only about a quarter assessed osteoporotic and metabolic risk before starting treatment. Three-quarters recommended exercise, yet only 25% had access to exercise programmes.
2014–2015 (17 papers)
Corrigendum re: "Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy"
Srivastava A (first author), Eur Urol 2015
Published erratum to the 2013 Eur Urol paper listed below; no abstract on PubMed.
Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database
Tsikkinis A (first author), Eur Urol Focus 2015
A September 2014 snapshot identified 123 phase 3 prostate cancer trials with pending results, 67% in non-metastatic disease. Systemic treatments were tested more often than local ones (58% vs 28%), led by androgen deprivation and radiotherapy respectively.
Systematic ultrasound-guided saturation and template biopsy of the prostate: indications and advantages of extended sampling
Isbarn H (first author), Arch Esp Urol 2015
Non-systematic review (2000–2013): saturation biopsy of 18 or more cores detected more cancer in men with lower PSA, larger prostates, lower PSA density and at repeat biopsy. Very extensive sampling raised urinary retention but not clearly sepsis; most data were retrospective.
Organ-confined prostate cancer: are we moving towards more or less radical surgical intervention?
Stevens DJ (first author), Curr Urol Rep 2015
Review of options for clinically localised disease, from surveillance and focal therapy to radiotherapy and surgery. Citing studies showing survival advantages for prostatectomy, the authors argue it should be the gold standard for most men.
What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series
Gandaglia G (first author), Urol Oncol 2015
In 1,710 surveillance-eligible men who had prostatectomy, 5-year biochemical recurrence-free survival was 97.0% for organ-confined Gleason 6 or less, 94.7% for organ-confined 3+4 and 79.1% for non-organ-confined, 4+3 or higher, or node-positive disease. Only that last group had significantly higher recurrence risk.
Surgical margin length and location affect recurrence rates after robotic prostatectomy
Dev HS (first author), Urol Oncol 2015
In 4,001 men with at least three years of follow-up, biochemical recurrence occurred in 37% with positive margins and 10% with negative margins (HR 1.81). Margins of 3 mm or more, multifocal margins and apical location (HR 2.03 vs basal) carried higher risk.
Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review
Surcel CI (first author), Urol Oncol 2015
Review of 59 articles (1993–2013): neuroendocrine markers may help predict outcomes in men on androgen deprivation, but evidence for independent prognostic value in hormone-naïve disease is weak. Data are insufficient to recommend routine use.
Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients
Ploussard G (first author), Urol Oncol 2015
Among 2,323 men with biopsy Gleason 3+4 who had prostatectomy at six centres, 46% had unfavourable disease. With none of four risk factors (PSA above 10, PSA density above 0.15, stage above T1, more than two positive cores) the rate was 19%, supporting expansion only with strict selection.
Real-time in vivo periprostatic nerve tracking using multiphoton microscopy in a rat survival surgery model: a promising pre-clinical study for enhanced nerve-sparing surgery
Durand M (first author), BJU Int 2015
In a rat survival model, multiphoton microscopy imaged and tracked periprostatic nerves in real time without contrast agents or motion artefact. There were no serious adverse events or laser-related tissue damage on histology.
The oncologic role of local treatment in primary metastatic prostate cancer
Ghadjar P (first author), World J Urol 2015
Review (1990 to April 2014): retrospective and population data suggest local treatment of the prostate may improve cancer-specific and overall survival over hormone therapy alone. With no RCTs available, the authors call for prospective trials.
Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey
Surcel CI (first author), BJU Int 2015
Survey of 585 European urologists (from 12,850 invited): prostatectomy followed by radiotherapy with androgen deprivation was the most common multimodal approach (60%). Adjuvant and salvage practice was highly heterogeneous, with no consensus on recurrence definitions.
The impact of length and location of positive margins in predicting biochemical recurrence after robot-assisted radical prostatectomy with a minimum follow-up of 5 years
Sooriakumaran P (first author), BJU Int 2015
In 904 men at one European centre, margins over 3 mm or multifocal were linked to higher biochemical recurrence than negative margins (HR 2.84, 95% CI 1.76–4.59). Unifocal margins of 3 mm or less were not significant, and a prognostic role for location was not confirmed.
PROSPECTIV — a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial
Watson E (first author), BMJ Open 2014
Protocol for a two-phase study: a survey of 300 men 9–24 months after diagnosis, then a pilot RCT of a nurse-led self-management intervention versus usual care (40 per arm). Primary outcome is change in prostate cancer-related quality of life; no results reported.
Authors' reply to Roach
Sooriakumaran P (first author), BMJ 2014
Authors' reply to correspondence in the BMJ; no abstract on PubMed. It most likely concerns the BMJ surgery versus radiotherapy study in the next row.
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes
Sooriakumaran P (first author), BMJ 2014
Swedish study of 34,515 men treated with surgery (21,533) or radiotherapy (12,982) in 1996–2010, followed up to 15 years. In non-metastatic disease, prostate cancer mortality was higher with radiotherapy (adjusted subdistribution HR 1.76, 95% CI 1.49–2.08); no clear difference in metastatic disease.
Reply to Giannarini, Suardi and Briganti's letter re: A multinational, multi-institutional study comparing positive surgical margin rates among 22 393 open, laparoscopic, and robot-assisted radical prostatectomy patients
Sooriakumaran P (first author), Eur Urol 2014
Authors' reply to a letter about the margin-rate study in the next row; no abstract on PubMed.
A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients
Sooriakumaran P (first author), Eur Urol 2014
Across 14 institutions, crude positive margin rates were 13.8% robotic, 16.3% laparoscopic and 22.8% open, with differences narrowing after adjustment. Lower-volume centres had higher margin risk for laparoscopic and robotic cases.
2012–2013 (18 papers)
Future prospects: who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches?
Ayres BE (first author), Curr Opin Urol 2013
Review of management of high-risk disease as a heterogeneous group needing treatment tailored to individual risk factors. More extensive surgery may prolong survival but could affect function, and well-designed RCTs are needed.
The European Association of Urology Robotic Urology Section (ERUS) survey of robot-assisted radical prostatectomy (RARP)
Ficarra V (first author), BJU Int 2013
January 2012 survey of 145 ERUS robotic surgeons (116 responded, 79.4%): the transperitoneal antegrade approach was most common. Practice varied in energy use for seminal vesicle dissection and in posterior and anterior reconstruction.
Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing
Tewari AK (first author), World J Urol 2013
In 1,335 single-surgeon cases with at least one year of follow-up, potency was 90.6%, 76.2%, 60.5% and 57.1% and continence 98%, 93.2%, 90.1% and 88.9% across nerve-sparing grades 1 to 4. Positive margin rates (10.5%, 7%, 5.8%, 4.8%) did not differ significantly (P = 0.064).
Reply from Authors re: Murphy and Costello, "How Can the Autonomic Nervous System Contribute to Urinary Continence Following Radical Prostatectomy?": Sparing of the Neurovascular Bundle Leads to Improved Rates of Continence
Tewari A (first author), Eur Urol 2013
Authors' reply to an editorial; no abstract on PubMed. PubMed tags this record "Retracted Publication" — check the record for the retraction notice.
Effect of a risk-stratified grade of nerve-sparing technique on early return of continence after robot-assisted laparoscopic radical prostatectomy
Srivastava A (first author), Eur Urol 2013
In 1,417 single-surgeon cases, 55.8% were pad-free by 12 weeks: 71.8%, 54.7%, 45.7% and 43.5% across nerve-sparing grades 1 to 4. Nerve-sparing grade independently predicted early continence, and margin rates did not differ (P = 0.111).
Assessment of required nodal yield in a high risk cohort undergoing extended pelvic lymphadenectomy in robotic-assisted radical prostatectomy and its impact on functional outcomes
Sagalovich D (first author), BJU Int 2013
Among 82 high-risk men, node positivity was 13.4%, and yields of 13 or more nodes found more positive nodes (21% vs 5%, P = 0.036). Potency recovery was lower with 20 or more nodes removed (55.2% vs 70%), with no difference in continence.
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis
Grisanzio C (first author), Proc Natl Acad Sci U S A 2012
Twelve risk variants were tested against transcript levels in 662 prostate tissue samples from 483 men; four were strongly linked to five transcripts in normal tissue. Suppressing NUDT11, SLC22A3 or HNF1B changed tumour-related traits in prostate cancer cells.
Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years
Sooriakumaran P (first author), Eur Urol 2012
In 944 men treated at Karolinska in 2002–2006 (median follow-up 6.3 years), biochemical recurrence-free survival was 87.1% at 5 years, 84.5% at 7 and 82.6% at 9. Higher PSA, Gleason 4+3 or more, pT3, positive margins and lower surgeon volume predicted recurrence.
Apples and oranges: comparison of treatment methods for prostate cancer using biochemical recurrence as an endpoint
Sooriakumaran P (first author), BJU Int 2012
No abstract on PubMed. The title questions comparing prostate cancer treatments using biochemical recurrence as the endpoint.
Cystolithotomy during robotic radical prostatectomy: Single-stage procedure for concomitant bladder stones
Tan GY (first author), Indian J Urol 2012
Case report of single-stage robotic removal of multiple bladder stones during robotic prostatectomy in a 64-year-old man. It was feasible, added little operative time and avoided a separate anaesthetic.
The impact of multiple biopsies on outcomes of nerve-sparing robotic-assisted radical prostatectomy
Sooriakumaran P (first author), Int J Impot Res 2012
Matched comparison of 50 men with one prior biopsy and 23 with multiple biopsies, all having nerve-sparing surgery by one surgeon. Continence was similar at 3 and 6 months, but 6-month erectile function was worse after multiple biopsies (57% vs 80%, P = 0.03).
Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy
Tewari A (first author), Eur Urol 2012
Pooling 400 articles and about 287,000 patients, robotic surgery had margin rates at least equivalent to open and laparoscopic surgery after propensity adjustment, with fewer total perioperative complications. Minimally invasive approaches had less blood loss, fewer transfusions and shorter stays than open surgery.
Advances in imaging the neurovascular bundle
Rai S (first author), Curr Opin Urol 2012
Review of methods to visualise the neurovascular bundle before, during and after prostatectomy. Multiphoton microscopy, optical coherence tomography, coherent anti-Stokes Raman spectroscopy and PSMA-based fluorescence imaging are highlighted as promising.
Optimizing radical prostatectomy for the early recovery of urinary continence
Dev HS (first author), Nat Rev Urol 2012
Review proposing a ten-step composite approach to speed continence recovery without compromising cancer control. Steps include protecting the sphincter and its nerves, maximising urethral length, a watertight anastomosis and fascioligamentous support.
Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification
Ficarra V (first author), Eur Urol 2012
Trifecta and pentafecta reporting could be applied correctly to only 28–62% of patients. The authors propose the SCP classification, applicable to all prostatectomy patients, with validation still to come.
Nerve sparing can preserve orgasmic function in most men after robotic-assisted laparoscopic radical prostatectomy
Tewari A (first author), BJU Int 2012
Among 408 potent men, orgasm was preserved in 88.4% aged 60 or under versus 82.6% of older men. It was preserved in 90.7% after bilateral nerve sparing versus 60.8% after non-nerve-sparing surgery.
Technique of traction-free nerve-sparing robotic prostatectomy: delicate tissue handling by real-time penile oxygen monitoring
Tewari A (first author), Int J Impot Res 2012
64 patients with intraoperative penile oxygen monitoring, where dissection was modified when saturation fell, were compared with 192 matched controls. After bilateral nerve sparing, freedom from erectile dysfunction was higher with monitoring at 6 weeks (24.5% vs 10.4%) and 52 weeks (83.7% vs 68%).
Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer
Sooriakumaran P (first author), Int Urol Nephrol 2012
Of 750 men meeting active surveillance criteria who had prostatectomy, 303 (40.4%) were upgraded or upstaged. PSA, number of positive cores and prostate volume predicted this and formed a nomogram, suggesting criteria may be too lenient.
2010–2011 (15 papers)
Pathological outcomes and strategies to achieve optimal cancer control during robotic radical prostatectomy in Asian-Indian men
Tewari AK (first author), Indian J Urol 2011
Comparing 56 Asian-Indian and 2,025 Caucasian men with D'Amico low-risk disease, extraprostatic extension was more common in Asian-Indian men (32.3% vs 16.5%). Biochemical recurrence-free rates were similar at median 16 months (94.6% vs 95.4%), and a nomogram for extraprostatic extension was developed.
Learning curve for robotic assisted laparoscopic prostatectomy: a multi-institutional study of 3794 patients
Sooriakumaran P (first author), Minerva Urol Nefrol 2011
Across three surgeons at three centres, positive margin rates kept improving, needing over 1,600 cases to fall below 10%, with the pT3 curve levelling after 1,000–1,500 cases. Operative time plateaued near 750 cases and then began rising again.
Anatomical grades of nerve sparing: a risk-stratified approach to neural-hammock sparing during robot-assisted radical prostatectomy (RARP)
Tewari AK (first author), BJU Int 2011
In 1,263 preoperatively potent men graded 1 to 4 for nerve sparing, intercourse (90.9%) and return to baseline sexual function (81.7%) were highest in grade 1 and fell with each grade. Positive margin rates were similar across grades (7.2–9.9%).
Models to predict positive prostate biopsies using the Tyrol screening study
Sooriakumaran P (first author), Urology 2011
Two nomograms built from 2,271 Tyrol screening biopsies (age, rectal examination, total PSA, with or without percent free PSA) were well calibrated. Both discriminated well internally and in an external cohort of 599 men, with the free PSA model performing better.
Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies
Dev H (first author), J Transl Med 2011
In 186 samples from 142 biobanked robotic prostatectomies, non-stromal samples had a mean RNA integrity number of 7.25. Warm ischaemia of about 120 minutes did not significantly affect RNA integrity, and roughly 40% of each specimen could be banked without compromising pathology.
The success of focal therapy hinges on the success of imaging platforms
Sooriakumaran P (first author), BJU Int 2011
No abstract on PubMed. The title argues that focal therapy depends on the performance of imaging.
Robotic-assisted laparoscopic prostatectomy: a critical analysis of its impact on urinary continence
Srivastava A (first author), Curr Opin Urol 2011
Review of technical refinements intended to speed continence recovery after robotic prostatectomy. Careful tissue handling, preserving support structures and restoring near-normal anatomy may improve early continence without compromising oncological outcomes.
Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk
Sooriakumaran P (first author), Expert Rev Anticancer Ther 2011
Commentary on ERSPC data stratified by age and baseline PSA: the trial's 20% relative mortality reduction brought minimal benefit for men aged 55–74 with PSA below 4 ng/ml. It argues for targeting screening at men at highest risk of prostate cancer death.
Prostate volume and its correlation with histopathological outcomes in prostate cancer
Sooriakumaran P (first author), Urol Int 2011
In 2,207 robotic prostatectomy patients, men with smaller prostates were younger with lower PSA but had worse Gleason sums, tumour volume and extraprostatic extension. Positive margins were 11.5% in small, 8.3% in intermediate and 5.6% in large prostates (p = 0.008).
Neuroanatomic basis for traction-free preservation of the neural hammock during athermal robotic radical prostatectomy
Srivastava A (first author), Curr Opin Urol 2011
Review of the anatomy of the erectile nerves and its surgical implications. It describes three surgically identifiable zones: the proximal neurovascular plate, the predominant neurovascular bundle and accessory neural pathways.
Dorsal vein complex control after apical dissection results in low apical positive surgical margins, but other surgical maneuvers are required to optimize early continence recovery
Sooriakumaran P (first author), Eur Urol 2011
Editorial comment; no abstract on PubMed. The title states that delayed dorsal vein control lowers apical margins but that other manoeuvres are needed for early continence.
A cohort study investigating patient expectations and satisfaction outcomes in men undergoing robotic assisted radical prostatectomy
Douaihy YE (first author), Int Urol Nephrol 2011
Of 377 consecutive patients given structured preoperative education (50% returned questionnaires), 93% were satisfied and 0.5% regretted surgery. Biochemical recurrence and incontinence lowered satisfaction, and 97% ranked oncological outcome as their top priority.
Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer
Sooriakumaran P (first author), Eur Urol 2010
Commentary on the Andriole et al. dutasteride trial; no abstract on PubMed.
Use of a novel absorbable barbed plastic surgical suture enables a "self-cinching" technique of vesicourethral anastomosis during robot-assisted prostatectomy and improves anastomotic times
Tewari AK (first author), J Endourol 2010
In 50 patients versus 50 earlier controls by the same surgeon, a barbed-suture technique cut anastomosis time from 12 to 7 minutes and posterior reconstruction from 60 to 40 seconds (p ≤ 0.001). Total operative time fell from 114.5 to 106 minutes.
Clinicopathological strategies to identify contralateral prostate cancer involvement in potential candidates for focal therapy
Grover S (first author), Int J Surg Pathol 2010
Of 1,114 robotic prostatectomy patients with unilateral disease on biopsy, 77.9% had contralateral or bilateral disease on final pathology. High-grade PIN on biopsy predicted contralateral involvement, and the authors suggest it as an exclusion criterion for focal therapy.
2004–2009 (15 papers)
The central urology multidisciplinary team - is it time to change the referral criteria? An audit of practice in a district general hospital in London
Sooriakumaran P (first author), Ann R Coll Surg Engl 2009
Audit of 2007 referrals: the central team changed management in 4 of 19 bladder cancer cases but in none of 67 prostate cancer cases, advising on or excluding 6 (9.0%) from trials. The authors question its added value for non-metastatic prostate cancer. Covers bladder and kidney cancer as well.
A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer
Sooriakumaran P (first author), Cancer Genomics Proteomics 2009
Phase II pilot RCT of 28 days of celecoxib or no drug before prostatectomy, with microarray profiling of tumour tissue. Twenty-four genes were up-regulated and four down-regulated, consistent with increased apoptosis and tumour suppressor activity.
A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer
Sooriakumaran P (first author), Anticancer Res 2009
45 men were randomised to celecoxib 400 mg twice daily or no treatment for four weeks before prostatectomy. Celecoxib reduced proliferation, microvessel density, angiogenesis and HIF-1 and enhanced apoptosis, though several effects only approached significance on multivariate analysis.
A novel method of obtaining prostate tissue for gene expression profiling
Sooriakumaran P (first author), Int J Surg Pathol 2009
A simple, inexpensive sampling method yielded enough RNA for microarray analysis without affecting histopathological assessment of the specimen. Validation showed over 95% sensitivity and 99% specificity for predicting the histology of the tissue obtained.
Minimally invasive surgical modalities in the management of localized prostate cancer
Jamal K (first author), Expert Rev Anticancer Ther 2008
Review of minimally invasive prostatectomy and energy-based treatments such as HIFU for localised disease. It compares their techniques and early oncological and functional outcomes with open prostatectomy.
COX-2 inhibition: a possible role in the management of prostate cancer?
Sooriakumaran P (first author), J Chemother 2007
Review of coxibs in prostate cancer and their cardiovascular risk profile. Celecoxib appears safer than other coxibs, possibly through lower COX-2 selectivity, which may also allow COX-2-independent anticancer effects.
Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy
Khaksar SJ (first author), BJU Int 2006
In 300 men treated with iodine-125 brachytherapy in 1999–2003 (median follow-up 45 months), 5-year PSA relapse-free survival was 93%, with no difference by risk group or neoadjuvant androgen deprivation. Acute retention occurred in 7%, and 62% of previously potent men remained so at 2 years.
Management of prostate cancer. Part 3: metastatic disease
Shah J (first author), Expert Rev Anticancer Ther 2006
Review of continuous and intermittent androgen deprivation, options in hormone-refractory disease, radiotherapy, radiopharmaceuticals and bisphosphonates. It notes the survival benefit of docetaxel in hormone-refractory disease and emerging targeted agents.
Management of prostate cancer. Part 2: localized and locally advanced disease
Sooriakumaran P (first author), Expert Rev Anticancer Ther 2006
Review of active surveillance, prostatectomy, brachytherapy, external beam radiotherapy and watchful waiting for localised disease, with rationale, outcomes and toxicity. It also surveys evolving evidence in locally advanced disease.
Management of prostate cancer. Part 1: chemoprevention
Sooriakumaran P (first author), Expert Rev Anticancer Ther 2006
Critical review of chemopreventive agents acting on sex steroids, oxidative stress, proliferation and apoptosis, and COX-2. Level 1 evidence and reliable surrogate biomarkers are lacking, giving little support for recommending any specific agent.
The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: a review
Sooriakumaran P (first author), Int J Surg 2005
Review noting that COX-2 is raised in prostate adenocarcinoma and in precancerous inflammatory atrophy, making it a chemoprevention target. Despite cardiovascular concerns with coxibs, there was no evidence of added risk from short-term neoadjuvant celecoxib.
Angiogenesis and the tumour hypoxia response in prostate cancer: a review
Sooriakumaran P (first author), Int J Surg 2005
Review of how new vessel formation supports prostate tumour growth and metastasis, with VEGF as the key mediator. Hypoxia stimulates angiogenesis, and understanding this could guide anti-angiogenic treatment.
Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer
Sooriakumaran P (first author), Clin Oncol (R Coll Radiol) 2005
Referring and reference pathologists agreed fully on Gleason score in only 52% of 83 brachytherapy referrals (kappa 0.27), with the reference pathologist scoring higher in 36 of 40 disagreements. Sixteen cases (19%) changed risk group, 15 of them to a worse group.
Brachytherapy: the surgeon's perspective
Henderson A (first author), BJU Int 2004
Letter commenting on a published article; no abstract on PubMed. The title gives a surgeon's view of brachytherapy.
Urinary morbidity after 125I brachytherapy of the prostate
Henderson A (first author), BJU Int 2004
Letter commenting on a published article; no abstract on PubMed. The title concerns urinary morbidity after iodine-125 prostate brachytherapy.